Komori
Earnings4523Eisai Co.,Ltd.Pharmaceuticals

Preliminary revenue from sales of the anti-amyloid beta antibody Leqembi

Preliminary global revenue from the anti-amyloid beta antibody Leqembi for the first quarter of FY2026 was announced. Revenue was ¥29.3 billion, exceeding the ¥23.1 billion reported for the same period of the previous year.

Worth reading
22Immaterial
Scored from 4 of 6 sections
Direction
Improvement
Direction inferred from the company’s description.
Scale
293
¥ million
Wording
Avoiding a definitive answer
How definitive the wording is.

Results for this period

First quarter1 April 2026 to 30 June 2026
Net Sales293¥ million

The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit.

Regional salesRegion United States / Current fiscal year ¥154 million / Prior-year period ¥91 million, Region Japan / Current fiscal year ¥61 million / Prior-year period ¥55 million, Region China / Current fiscal year ¥48 million / Prior-year period ¥77 million
Factors Behind Changes in Business Performance

Revenue for the same period of the previous year was ¥23.1 billion, including an estimated ¥5.3 billion impact from distributors building up inventories in China.

Results for this period
ItemDetails
Fiscal Period ClassificationFirst quarter
Period Covered1 April 2026 to 30 June 2026
Net Sales¥293 million
Regional salesRegion United States / Current fiscal year ¥154 million / Prior-year period ¥91 million, Region Japan / Current fiscal year ¥61 million / Prior-year period ¥55 million, Region China / Current fiscal year ¥48 million / Prior-year period ¥77 million
Factors Behind Changes in Business PerformanceRevenue for the same period of the previous year was ¥23.1 billion, including an estimated ¥5.3 billion impact from distributors building up inventories in China.
Items this document does not state (33)
Accounting standardsConsolidated / non-consolidatedOperating profitOrdinary incomeProfit attributable to owners of the parentNet income per shareOperating MarginEquity ratioTotal assetsNet assetsCash flows from operating activitiesCash flows from investing activitiesCash flows from financing activitiesCash and cash equivalents at end of periodFull-year earnings forecastRevision to Earnings ForecastAnnual Dividend ForecastPayout ratioShareholder Return PolicySegment revenueSegment profitOrders received and order backlogDepreciation and amortizationImpairment lossBreakdown of extraordinary income (loss)Disclosure regarding the going concern assumptionChange in accounting policyChanges in the scope of consolidationMaterial subsequent eventsAvailability of Supplementary Financial Results MaterialsAvailability of Financial Results BriefingIssued Shares at Period-EndTreasury Shares at Period-End

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

Revenue for the same period of the previous year included an estimated ¥5.3 billion impact from distributors building up inventories in China.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Preliminary revenue from sales of the anti-amyloid beta antibody Leqembi | Eisai Co.,Ltd. (4523) timely disclosure | Komori